43 / 74 · 0:50 · Original AXON film
Eloralintide
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
Amylin-receptor research
Eloralintide targets amylin receptors, part of the biology of appetite. Its clinical evidence is best understood by looking at the actual trial. [1]
Phase 2 | 263 adults
A 2025 randomized, placebo-controlled phase two study followed 263 adults with obesity or overweight and a related condition, without type two diabetes. [1]
48-week weight outcome
Over 48 weeks, treated groups lost more weight than the placebo group. Nausea and fatigue were among the most common reported adverse events. [1]
Keep the trial boundaries
Those findings describe selected participants, a defined formulation, and a limited follow-up period. They cannot establish lifelong safety or validate unrelated products bearing the same name. [1]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Billings et al. (2025): Eloralintide, a selective amylin receptor agonist for the treatment of obesity →Study design, population, 48-week body-weight findings, nausea, and fatigue.
